Skip to content

MUPPET; Motor Unit and muscle strength changes in PostPolio syndrome, Evaluation after Ten years.

MUPPET; Motor Unit and muscle strength changes in PostPolio syndrome, Evaluation after Ten years. - MUPPET

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON34659
Enrollment
80
Registered
2010-05-19
Start date
2010-07-12
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpoliomyelitis Syndrome PPS

Interventions

None listed

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: (1) All PPS subjects who participated in the trial by Horemans et al in 1999-2000* (2) All controls who participated in the study described by Drost et al in the same period**;* Horemans HL, Nollet F, Beelen A et al. Pyridostigmine in postpolio syndrome: no decline in fatigue and limited functional improvement. J Neurol Neurosurg Psychiatry. 2003;74:1655-1661 **Drost G, Stegeman DF, Schillings ML et al. Motor unit characteristics in healthy subjects and those with postpoliomyelitis syndrome: a high-density surface EMG study. Muscle Nerve. 2004;30:269-276.

Exclusion criteria

Exclusion criteria: All participants of the trials of Horemans et al and Drost et al are eligible for participation unless they suffer from: (1) Legal incompetence (incapacity), e.g. due to dementia (2) Motor neuron disease or neurological disease that affects voluntary control of the quadriceps muscle under investigation.

Design outcomes

Primary

MeasureTime frame
Changes in maximal quadriceps strength and motor unit size since baseline measurements 10 years ago.

Secondary

MeasureTime frame
Secondary parameters are changes in walking capacity, daily walking activity, physical functioning, fatigue and additional motor unit characteristics.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)